Cargando…

A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease

BACKGROUND: In preclinical models, antagonism of metabotropic glutamate receptor 5 (mGluR5) reduces transient lower oesophageal sphincter relaxations (TLOSRs) and increases LOS pressure. This study evaluated the effect of ADX10059, a potent, selective, negative allosteric modulator of mGluR5, on oes...

Descripción completa

Detalles Bibliográficos
Autores principales: Keywood, C, Wakefield, M, Tack, J
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719084/
https://www.ncbi.nlm.nih.gov/pubmed/19460767
http://dx.doi.org/10.1136/gut.2008.162040
_version_ 1782170050925428736
author Keywood, C
Wakefield, M
Tack, J
author_facet Keywood, C
Wakefield, M
Tack, J
author_sort Keywood, C
collection PubMed
description BACKGROUND: In preclinical models, antagonism of metabotropic glutamate receptor 5 (mGluR5) reduces transient lower oesophageal sphincter relaxations (TLOSRs) and increases LOS pressure. This study evaluated the effect of ADX10059, a potent, selective, negative allosteric modulator of mGluR5, on oesophageal pH-metry and clinical symptoms in GORD. METHODS: Two groups of patients with GORD (n = 12 per group) underwent 24-h oesophageal pH-metry on two sequential treatment days. The patients received oral placebo three times daily (tds) 30 min before a high-fat meal on Day 1 and oral ADX10059 50 mg (Group 1) or 250 mg (Group 2) tds 30 min before a high-fat meal on Day 2. The primary variable was acid exposure (%time pH<4). Secondary variables included number and duration of reflux episodes, number and duration of symptomatic episodes and symptoms recorded in diaries. Comparisons were made for Day 2 (active) versus Day 1 (placebo) treatment and for Group 1 versus Group 2. RESULTS: ADX10059 250 mg tds significantly decreased the percentage of time with pH<4 from 7.2% to 3.6% (p = 0.01). ADX10059 250 mg tds reduced pH-metry-measured oesophageal acid exposure, throughout the 24 h period, nocturnally and postprandially, and significantly reduced the number and duration of symptomatic reflux episodes (p = 0.03). ADX10059 50 mg tds was not significantly superior to placebo. ADX10059 was generally well tolerated. CONCLUSION: The mGluR5 negative allosteric modulator ADX10059 reduced acid reflux which was associated with improvement in clinical symptoms in patients with GORD. ADX10059 appears to have a potential role in the clinical management of GORD.
format Text
id pubmed-2719084
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-27190842009-07-31 A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease Keywood, C Wakefield, M Tack, J Gut Oesophagus BACKGROUND: In preclinical models, antagonism of metabotropic glutamate receptor 5 (mGluR5) reduces transient lower oesophageal sphincter relaxations (TLOSRs) and increases LOS pressure. This study evaluated the effect of ADX10059, a potent, selective, negative allosteric modulator of mGluR5, on oesophageal pH-metry and clinical symptoms in GORD. METHODS: Two groups of patients with GORD (n = 12 per group) underwent 24-h oesophageal pH-metry on two sequential treatment days. The patients received oral placebo three times daily (tds) 30 min before a high-fat meal on Day 1 and oral ADX10059 50 mg (Group 1) or 250 mg (Group 2) tds 30 min before a high-fat meal on Day 2. The primary variable was acid exposure (%time pH<4). Secondary variables included number and duration of reflux episodes, number and duration of symptomatic episodes and symptoms recorded in diaries. Comparisons were made for Day 2 (active) versus Day 1 (placebo) treatment and for Group 1 versus Group 2. RESULTS: ADX10059 250 mg tds significantly decreased the percentage of time with pH<4 from 7.2% to 3.6% (p = 0.01). ADX10059 250 mg tds reduced pH-metry-measured oesophageal acid exposure, throughout the 24 h period, nocturnally and postprandially, and significantly reduced the number and duration of symptomatic reflux episodes (p = 0.03). ADX10059 50 mg tds was not significantly superior to placebo. ADX10059 was generally well tolerated. CONCLUSION: The mGluR5 negative allosteric modulator ADX10059 reduced acid reflux which was associated with improvement in clinical symptoms in patients with GORD. ADX10059 appears to have a potential role in the clinical management of GORD. BMJ Group 2009-09 2009-05-20 /pmc/articles/PMC2719084/ /pubmed/19460767 http://dx.doi.org/10.1136/gut.2008.162040 Text en © Keywood et al 2009 http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oesophagus
Keywood, C
Wakefield, M
Tack, J
A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title_full A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title_fullStr A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title_full_unstemmed A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title_short A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
title_sort proof-of-concept study evaluating the effect of adx10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
topic Oesophagus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719084/
https://www.ncbi.nlm.nih.gov/pubmed/19460767
http://dx.doi.org/10.1136/gut.2008.162040
work_keys_str_mv AT keywoodc aproofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease
AT wakefieldm aproofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease
AT tackj aproofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease
AT keywoodc proofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease
AT wakefieldm proofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease
AT tackj proofofconceptstudyevaluatingtheeffectofadx10059ametabotropicglutamatereceptor5negativeallostericmodulatoronacidexposureandsymptomsingastrooesophagealrefluxdisease